Combination of PD-1/PD-L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma.

"CONFLICT OF INTEREST Daphne Dumoulin reports personal fees from Roche, BMS, MSD, Pfizer, Astra Zeneca and Novartis outside the submitted work. Robin Cornelissen reports personal speaker fees from Roche, Pfizer and Bristol Myers Squibb, and personal advisory fees from MSD and Roche, outside the submitted work. Koen Bezemer reports personal fees from Amphera B.V. outside the submitted work. Joachim Aerts reports personal fees and nonfinancial support from MSD, personal fees from BMS, Boehringer Ingelheim, Amphera, Eli‐Lilly, Takeda, Bayer, Roche, Astra Zeneca outside the submitted work; in addition, Joachim Aerts has a patent allogenic tumor cell lysate licensed to Amphera, a patent combination immunotherapy in cancer pending, and a patent biomarker for immunotherapy pending; Joachim Aerts served as an unpaid editorial board member of Translational Lung Cancer Research from September 2019 to September 2021. The other authors do not have a conflict of interest to disclose."